Skip to content
CHEPLAPHARM Arzneimittel GmbH in agreement with the HPRA have released the following update on hydroxycarbamide-containing medicinal products.
Hydroxycarbamide may falsely elevate sensor glucose results from certain continuous glucose monitoring (CGM) systems which may lead to hypoglycaemia if sensor glucose results are relied upon to dose insulin.
CGM systems that are available in Ireland include products from Dexcom (Dexcom G6, G7, One+), Abbott Diabetes Care (FreeStyle Libre), Medtronic (Medtronic GuardianTM Sensor), and Windzor Pharma Ltd (GlucoRx AidexTM).
Hydroxycarbamide-containing medicinal products are authorised in haematological and oncological indications in Ireland. These products include Hydrea 500 mg Hard Capsules which is indicated in the management of malignant neoplastic disease including chronic myeloid leukaemia (pretreatment phase and palliative care) and is also indicated for treatment of cancer of the cervix and other solid type tumours in conjunction with radiotherapy.
If CGM systems are to be used concurrently with hydroxycarbamide treatment, consult with the CGM prescriber about the need to consider alternative glucose monitoring methods.
Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance, website: www.hpra.ie
